SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Decrease in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 58,800 shares, a decrease of 26.3% from the October 15th total of 79,800 shares. Based on an average daily volume of 64,100 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.8% of the shares of the stock are short sold.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ SABS traded down $0.60 during midday trading on Friday, reaching $3.10. The company’s stock had a trading volume of 84,880 shares, compared to its average volume of 30,583. SAB Biotherapeutics has a one year low of $2.16 and a one year high of $9.72. The company has a 50 day moving average price of $2.95 and a 200 day moving average price of $2.98. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. Equities research analysts expect that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned approximately 0.21% of SAB Biotherapeutics at the end of the most recent quarter. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on SABS shares. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Oppenheimer reiterated an “outperform” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Chardan Capital restated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a research report on Thursday, November 7th. Finally, Craig Hallum began coverage on SAB Biotherapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $11.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $12.40.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.